Daysha Fliginger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daysha Fliginger has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Lisa Eisler
Anesthesiology, Columbia University Irving Medical Center, New York, NY
2 shared publications - Alexey V. Dimov
Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA
1 shared publication - Christian Habeck
Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY 10032, USA
1 shared publication - Daniel A. Ortega
Columbia University Vagelos College of Physicians and Surgeons
1 shared publication - David Roh
Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA
1 shared publication - Debra A. Kessler
New York Blood Center, New York, New York, USA
1 shared publication
Latest Publications
- 2 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics
Cell Saver Use is Not Associated With Increased Morbidity But Reflects Transfusion Burden in Pediatric Spinal Deformity Surgery: A Retrospective Cohort Study
Study Design: Retrospective cohort study. Introduction: Cell saver (CS) is widely used in spinal fusion to reduce exposure to allogeneic transfusion, which carries risks such as infection and prolonged hospitalization. Pediatric spinal fusion is frequently associated with significant intraoperative blood loss. Concerns persist that reinfused blood could increase morbidity. We therefore evaluated the association between CS exposure and postoperative outcomes after pediatric spinal fusion using the American College of Surgeons National Surgical Quality Improvement Program Pediatric database. Methods: Among patients who underwent spinal fusion surgery for pediatric spinal deformity between 2021 and 2023, CS exposure was categorized as none, low (P 0.05). Neurological complications varied significantly ( P =0.013), but only the high CS versus no CS comparison was significant (OR=1.60; P =0.015). Intraoperative allogeneic transfusion rates differed ( P P P <0.001). Conclusions: CS use was not associated with increased overall morbidity within 30 days. High CS volume identified a subgroup with higher odds of neurological complications and greater transfusion rates, likely reflecting residual confounding or bleeding severity rather than a direct CS effect. Low CS exposure was associated with reduced allogeneic transfusions. Level of Evidence: Level III.
- 2 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics
Cell Saver Use is Not Associated With Increased Morbidity But Reflects Transfusion Burden in Pediatric Spinal Deformity Surgery: A Retrospective Cohort Study
Study Design: Retrospective cohort study. Introduction: Cell saver (CS) is widely used in spinal fusion to reduce exposure to allogeneic transfusion, which carries risks such as infection and prolonged hospitalization. Pediatric spinal fusion is frequently associated with significant intraoperative blood loss. Concerns persist that reinfused blood could increase morbidity. We therefore evaluated the association between CS exposure and postoperative outcomes after pediatric spinal fusion using the American College of Surgeons National Surgical Quality Improvement Program Pediatric database. Methods: Among patients who underwent spinal fusion surgery for pediatric spinal deformity between 2021 and 2023, CS exposure was categorized as none, low (P 0.05). Neurological complications varied significantly ( P =0.013), but only the high CS versus no CS comparison was significant (OR=1.60; P =0.015). Intraoperative allogeneic transfusion rates differed ( P P P <0.001). Conclusions: CS use was not associated with increased overall morbidity within 30 days. High CS volume identified a subgroup with higher odds of neurological complications and greater transfusion rates, likely reflecting residual confounding or bleeding severity rather than a direct CS effect. Low CS exposure was associated with reduced allogeneic transfusions. Level of Evidence: Level III.
- Open Access
- 21 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Effects of iron repletion on brain iron content, myelination, neural network activation, and cognition
BACKGROUND: Blood donation increases the risk of iron deficiency, but its effect on brain iron, myelination, and neurocognition remains unclear. METHODS: This ancillary study enrolled 67 iron-deficient blood donors, 19–73 years of age, participating in a double-blind, randomized trial. After donating blood, positive and negative susceptibility were measured using quantitative susceptibility mapping (QSM) MRI to estimate brain iron and myelin levels, respectively. Furthermore, neurocognitive function was evaluated using the NIH Toolbox, and neural network activation patterns were assessed during neurocognitive tasks using functional MRI (fMRI). Donors were randomized to i.v. iron repletion (1 g iron) or placebo, and outcome measures repeated approximately 4 months later. RESULTS: Iron repletion corrected systemic iron deficiency and led to trends toward increased whole brain iron ( P = 0.04) and myelination ( P = 0.02), with no change in the placebo group. Although overall cognitive performance did not differ significantly between groups, iron-treated participants showed improved engagement of functional neural networks (e.g., memory pattern activation during speed tasks, P < 0.001). Brain region-specific changes in iron and myelin correlated with cognitive performance: iron in the putamen correlated with working memory scores ( P < 0.01), and thalamic myelination correlated with attention and inhibitory control ( P < 0.01). CONCLUSION: Iron repletion in iron-deficient blood donors may influence brain iron, myelination, and function, with region-specific changes in iron and myelination linked to distinct cognitive domains. REGISTRATION: ClinicalTrials.gov NCT02990559 FUNDING: This work was funded by the NIH.
- 21 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Open AccessEffects of iron repletion on brain iron content, myelination, neural network activation, and cognition
BACKGROUND: Blood donation increases the risk of iron deficiency, but its effect on brain iron, myelination, and neurocognition remains unclear. METHODS: This ancillary study enrolled 67 iron-deficient blood donors, 19–73 years of age, participating in a double-blind, randomized trial. After donating blood, positive and negative susceptibility were measured using quantitative susceptibility mapping (QSM) MRI to estimate brain iron and myelin levels, respectively. Furthermore, neurocognitive function was evaluated using the NIH Toolbox, and neural network activation patterns were assessed during neurocognitive tasks using functional MRI (fMRI). Donors were randomized to i.v. iron repletion (1 g iron) or placebo, and outcome measures repeated approximately 4 months later. RESULTS: Iron repletion corrected systemic iron deficiency and led to trends toward increased whole brain iron ( P = 0.04) and myelination ( P = 0.02), with no change in the placebo group. Although overall cognitive performance did not differ significantly between groups, iron-treated participants showed improved engagement of functional neural networks (e.g., memory pattern activation during speed tasks, P < 0.001). Brain region-specific changes in iron and myelin correlated with cognitive performance: iron in the putamen correlated with working memory scores ( P < 0.01), and thalamic myelination correlated with attention and inhibitory control ( P < 0.01). CONCLUSION: Iron repletion in iron-deficient blood donors may influence brain iron, myelination, and function, with region-specific changes in iron and myelination linked to distinct cognitive domains. REGISTRATION: ClinicalTrials.gov NCT02990559 FUNDING: This work was funded by the NIH.